TGFB1 and neoplasm: TGF-β inhibition with the small TGF-β type 1 receptor kinase (ALK5) inhibitor SM16 increased the levels of neutrophil chemoattractants in the tumor microenvironment, resulting in neutrophil recruitment [14].